<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">The Clinician</journal-id><journal-title-group><journal-title xml:lang="en">The Clinician</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиницист</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8338</issn><issn publication-format="electronic">2412-8775</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">257</article-id><article-id pub-id-type="doi">10.17650/1818-8338-2016-10-2-32-42</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">POSSIBILITIES OF PHARMACOLOGICAL CORRECTION OF STRUCTURAL AND FUNCTIONAL ALTERATIONS OF MICROCIRCULATION IN TERMS OF ENDOTHELIAL DYSFUNCTION IN COMORBID PATIENTS SUFFERED STROKE EVENT</article-title><trans-title-group xml:lang="ru"><trans-title>ВОЗМОЖНОСТИ ФАРМАКОЛОГИЧЕСКОЙ КОРРЕКЦИИ СТРУКТУРНО-ФУНКЦИОНАЛЬНЫХ ИЗМЕНЕНИЙ МИКРОЦИРКУЛЯЦИИ В УСЛОВИЯХ ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ У КОМОРБИДНЫХ БОЛЬНЫХ, ПЕРЕНЕСШИХ ИНСУЛЬТ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zolotovskaya</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Золотовская</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Chair of hospital therapy with courses of outpatient therapy and transfusiology, </p><p>89 Chapaevskaya St., Samara, 443099</p></bio><bio xml:lang="ru"><p>Кафедра госпитальной терапии с курсами поликлинической терапии и трансфузиологии,</p><p>443099, Самара, ул. Чапаевская, 89</p></bio><email>zolotovskay@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Davydkin</surname><given-names>I. L.</given-names></name><name xml:lang="ru"><surname>Давыдкин</surname><given-names>И. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Chair of hospital therapy with courses of outpatient therapy and transfusiology, </p><p>89 Chapaevskaya St., Samara, 443099</p></bio><bio xml:lang="ru"><p>Кафедра госпитальной терапии с курсами поликлинической терапии и трансфузиологии,</p><p>443099, Самара, ул. Чапаевская, 89</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Educational Institution of Higher Professional Education “Samara State Medical University” of the Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2016</year></pub-date><volume>10</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>32</fpage><lpage>42</lpage><history><date date-type="received" iso-8601-date="2016-09-16"><day>16</day><month>09</month><year>2016</year></date><date date-type="accepted" iso-8601-date="2016-09-16"><day>16</day><month>09</month><year>2016</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Zolotovskaya I.A., Davydkin I.L.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, Золотовская И.А., Давыдкин И.Л.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Zolotovskaya I.A., Davydkin I.L.</copyright-holder><copyright-holder xml:lang="ru">Золотовская И.А., Давыдкин И.Л.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://klinitsist.abvpress.ru/Klin/article/view/257">https://klinitsist.abvpress.ru/Klin/article/view/257</self-uri><abstract xml:lang="en"><p><bold>Aim of the study –</bold> reveal clinical efficacy of naftidrofuryl in the aspect of correcting structural and functional changes of microcirculation (MC) in relation to the influence of the endothelial dysfunction (ED) parameters in comorbid patients suffered stroke event.</p><p><bold>Materials and methods.</bold> The study included 95 patients suffered ischemic type of stroke in the carotid bassin. An average age of patients was 69.0 ± 5.3 years, stroke duration was 73.5 ± 8.4 days. Patients were randomized in 2 groups by using blind method of envelopes. The mentioned groups matched on the main clinical and demographic characteristics. Patients from the 1st group (primary group, n = 47) were treated with naftidrofuryl (Duzofarm) at the daily dose of 300 mg, 2 patients (comparison group, n = 48) received basic therapy only. 50 people without an acute cerebrovascular accident in history were allocated as a control group (group 3). The following blood biochemical parameters were assessed: glucose, creatinine, total cholesterol, high density lipoprotein; triglycerides; markers of endothelial dysfunction: von Willebrand factor (VWF), tissue plasminogen activator inhibitor-1 (PAI 1), antithrombin III (AT III) and plasminogen. MC was studied by the method of laser doppler flowmetry. The duration of the observation period was 6 months, and 4 visits were performed during this period.</p><p><bold>Results.</bold> Initial task of group formation within the study protocol has been solved by us in a full range. Patients from Group 1 that received naftidrofuryl noted statistically significant differences after 3 and 6 months of follow-up observation. These differences reflected improvement in perfusion index, coefficient of variation, as well as endothelial, neurogenic and myogenic regulation of microvasculature, increase in perfusion oxygen saturation index in the microcirculation. We have found that an index of relative perfusion oxygen saturation in microvascular blood (Sm) being the main indicator that reflects oxygen saturation of microcirculation has significantly correlated with ejection fraction, PAI1, AT III, and plasminogen levels in group 1 patients in 3 and 6 months. We have also found significant correlation with ED when comparing parameters that express endothelial, neurogenic and myogenic regulation of microvessels. These data clearly demonstrated an association between improving of MC parameters and ED parameters in Group 1 patients.</p><p><bold>Conclusion.</bold> Possibility of correction of MC alterations leading to the worsening of ischemia and ED progression is one of the most promising directions in the treatment of stroke patients. Aim of the drug therapy is to prevent ED progression, reduced vascular tone and restore an adequate level of tissue hemoperfusion.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель исследования —</bold> изучение клинической эффективности нафтидрофурила в аспекте коррекции структурно-функциональных изменений микроциркуляции (МЦ) во взаимосвязи с влиянием на параметры эндотелиальной дисфункции (ЭД) у коморбидных больных, перенесших инсульт.</p><p><bold>Материалы и методы.</bold> В исследование включены 95 пациентов, перенесших инсульт по ишемическому типу в каротидном бассейне. Средний возраст больных составил 69,0 ± 5,3 года, давность инсульта — 73,5 ± 8,4 дня. Пациенты были рандомизированы слепым методом конвертов в 2 группы, сопоставимые по основным клинико-демографическим показателям. Больным 1-й группы (основной, n = 47) назначен препарат нафтидрофурил (Дузофарм) в суточной дозе 300 мг, больные 2-й группы (сравнения, n = 48) получали только базовую терапию. В качестве контроля (3-я группа) были отобраны 50 человек без острого нарушения мозгового кровообращения в анамнезе. Определяли биохимические параметры крови: глюкозу, креатинин, общий холестерин, липопротеиды высокой плотности, триглицериды; уровни маркеров ЭД: фактора Виллебранда (ФВ), ингибитора тканевого активатора плазминогена-1 (PAI1), антитромбина III (АТ III) и плазминогена. Изучение МЦ проводили с помощью метода лазерной допплеровской флоуметрии. Длительность периода наблюдения составила 6 мес, в течение которых выполнены 4 визита.</p><p><bold>Результаты.</bold> Исходная задача по формированию групп в рамках протокола исследования была решена в полном объеме. Через 3 и 6 мес наблюдения у пациентов 1-й группы, получавших нафтидрофурил, отмечены статистически значимые различия, отражающие улучшение показателя средней перфузии, коэффициента вариации, а также эндотелиальной, нейрогенной и миогенной регуляции микрососудов, повышение перфузионной сатурации кислорода в микрокровотоке. Установлено, что индекс относительной перфузионной сатурации кислорода в микрокровотоке (Sm) — основной показатель, отражающий степень насыщения кислородом микрокровотока, – у больных 1-й группы через 3 и 6 мес статистически значимо коррелировал с уровнями ФВ, PAI1, АТ III, плазминогена. По параметрам, отражающим эндотелиальную, нейрогенную и миогенную регуляцию микрососудов, были отмечены корреляционные связи с показателями ЭД. Полученные данные наглядно демонстрируют связь между улучшением параметров МЦ и показателями ЭД у пациентов 1-й группы.</p><p><bold>Заключение.</bold> Возможность коррекции изменений на уровне МЦ, приводящих к усугублению ишемии и прогрессированию ЭД, является одним из перспективных направлений в комплексной терапии больных, перенесших инсульт. Задача лекарственной терапии — предотвратить прогрессирование ЭД, уменьшить сосудистый тонус и восстановить уровень адекватной гемоперфузии тканей.</p></trans-abstract><kwd-group xml:lang="en"><kwd>microcirculation</kwd><kwd>endothelial dysfunction</kwd><kwd>stroke</kwd><kwd>acute ischemic stroke</kwd><kwd>comorbidity</kwd><kwd>laser doppler flowmetry</kwd><kwd>index of relative perfusion oxygen saturation in microvascular blood</kwd><kwd>von Willebrand factor</kwd><kwd>tissue plasminogen activator inhibitor</kwd><kwd>antithrombin III</kwd><kwd>naftidrofuryl</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>микроциркуляция</kwd><kwd>эндотелиальная дисфункция</kwd><kwd>инсульт</kwd><kwd>острое нарушение мозгового кровообращения</kwd><kwd>коморбидность</kwd><kwd>лазерная допплеровская флоуметрия</kwd><kwd>индекс относительной перфузионной сатурации кислорода в микрокровотоке</kwd><kwd>фактор Виллебранда</kwd><kwd>ингибитор тканевого активатора плазминогена-1</kwd><kwd>антитромбин III</kwd><kwd>нафтидрофурил</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Лаборатория Самарской городской поликлиники №9</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121(4 Pt 1):1244–63.</mixed-citation><mixed-citation xml:lang="ru">Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121(4 Pt 1):1244–63.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Крупаткин А.И. Колебания кровотока - новый диагностический язык в исследовании микроциркуляции. Регионарное кровообращение и микроциркуляция 2014;13(1):83–99. [Krupatkin A.I. Variations of blood flow – a new diagnostic language to the study of the microcirculation. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya = Regional Hemodynamics and Microcirculation 2014;13(1):83–99. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Крупаткин А.И. Колебания кровотока - новый диагностический язык в исследовании микроциркуляции. Регионарное кровообращение и микроциркуляция 2014;13(1):83–99. [Krupatkin A.I. Variations of blood flow – a new diagnostic language to the study of the microcirculation. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya = Regional Hemodynamics and Microcirculation 2014;13(1):83–99. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Malpas S.C. The rhythmicity of sympathetic nerve activity. Prog Neurobiol 1998;56(1): 65–96.</mixed-citation><mixed-citation xml:lang="ru">Malpas S.C. The rhythmicity of sympathetic nerve activity. Prog Neurobiol 1998;56(1): 65–96.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Guild S.J., Barrett C.J., McBryde F.D. et al. Quantifying sympathetic nerve activity: problems, pitfalls and the need for standardization. Exp Physiol 2010;95(1): 41–50.</mixed-citation><mixed-citation xml:lang="ru">Guild S.J., Barrett C.J., McBryde F.D. et al. Quantifying sympathetic nerve activity: problems, pitfalls and the need for standardization. Exp Physiol 2010;95(1): 41–50.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Briant L.J., Burchell A.E., Ratcliffe L.E. et al. Quantifying sympathetic neurohaemodynamic transduction at rest in humans: insights into sex, ageing and blood pressure control. J Physiol 2016;594(17):4753–68.</mixed-citation><mixed-citation xml:lang="ru">Briant L.J., Burchell A.E., Ratcliffe L.E. et al. Quantifying sympathetic neurohaemodynamic transduction at rest in humans: insights into sex, ageing and blood pressure control. J Physiol 2016;594(17):4753–68.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Paparde A., Plakane L., Circenis K., Aivars J.I. Effect of acute systemic hypoxia on human cutaneous microcirculation and endothelial, sympathetic and myogenic activity. Microvasc Res 2015; 102:1–5.</mixed-citation><mixed-citation xml:lang="ru">Paparde A., Plakane L., Circenis K., Aivars J.I. Effect of acute systemic hypoxia on human cutaneous microcirculation and endothelial, sympathetic and myogenic activity. Microvasc Res 2015; 102:1–5.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Yokoyama T., Nakamuta N., Kusakabe T., Yamamoto Y. Sympathetic regulation of vascular tone via noradrenaline and serotonin in the rat carotid body as revealed by intracellular calcium imaging. Brain Res 2015;1596:126–35.</mixed-citation><mixed-citation xml:lang="ru">Yokoyama T., Nakamuta N., Kusakabe T., Yamamoto Y. Sympathetic regulation of vascular tone via noradrenaline and serotonin in the rat carotid body as revealed by intracellular calcium imaging. Brain Res 2015;1596:126–35.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Roy T.K., Secomb T.W. Functional sympatholysis and sympathetic escape in a theoretical model for blood flow regulation. Front Physiol 2014;5:192.</mixed-citation><mixed-citation xml:lang="ru">Roy T.K., Secomb T.W. Functional sympatholysis and sympathetic escape in a theoretical model for blood flow regulation. Front Physiol 2014;5:192.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Carda A.P., Marchi K.C., Rizzi E. et al. Acute restraint stress induces endothelial dysfunction: role of vasoconstrictor prostanoids and oxidative stress. Stress 2015;18(2):233–43.</mixed-citation><mixed-citation xml:lang="ru">Carda A.P., Marchi K.C., Rizzi E. et al. Acute restraint stress induces endothelial dysfunction: role of vasoconstrictor prostanoids and oxidative stress. Stress 2015;18(2):233–43.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Zhang S., Cui N., Li S. et al. Interception of the endotoxin-induced arterial hyporeactivity to vasoconstrictors. Vascul Pharmacol 2014;62(1):15–23.</mixed-citation><mixed-citation xml:lang="ru">Zhang S., Cui N., Li S. et al. Interception of the endotoxin-induced arterial hyporeactivity to vasoconstrictors. Vascul Pharmacol 2014;62(1):15–23.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Mahoney F.I., Barthel D.W. Functional evaluation: the Barthel index. Md State Med J 1965;14:61–5.</mixed-citation><mixed-citation xml:lang="ru">Mahoney F.I., Barthel D.W. Functional evaluation: the Barthel index. Md State Med J 1965;14:61–5.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Крупаткин А.И., Сидоров В.В. Лазерная допплеровская флоуметрия микроциркуляции крови. Руководство для врачей. М.: Медицина, 2005. [Krupatkin A.I., Sidorov V.V. Laser Doppler flowmetry blood microcirculation. Guidelines for doctors. Moscow: Meditsina, 2005. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Крупаткин А.И., Сидоров В.В. Лазерная допплеровская флоуметрия микроциркуляции крови. Руководство для врачей. М.: Медицина, 2005. [Krupatkin A.I., Sidorov V.V. Laser Doppler flowmetry blood microcirculation. Guidelines for doctors. Moscow: Meditsina, 2005. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Quan H., Sundararajan V., Halfon P. et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43(11):1130–9.</mixed-citation><mixed-citation xml:lang="ru">Quan H., Sundararajan V., Halfon P. et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43(11):1130–9.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Feinstein A.R. Pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 1970;23(7):455–68.</mixed-citation><mixed-citation xml:lang="ru">Feinstein A.R. Pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 1970;23(7):455–68.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Васильев А.П., Стрельцова Н.Н. Возрастные особенности микрогемоциркуляции. Регионарное кровообращение и микроциркуляция 2012;11(4):23–7. [Vasil’ev A.P., Strel’tsova N.N. Age peculiarities of the microcirculation. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya = Regional Hemodynamics and Microcirculation 2012;11(4):23–7. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Васильев А.П., Стрельцова Н.Н. Возрастные особенности микрогемоциркуляции. Регионарное кровообращение и микроциркуляция 2012;11(4):23–7. [Vasil’ev A.P., Strel’tsova N.N. Age peculiarities of the microcirculation. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya = Regional Hemodynamics and Microcirculation 2012;11(4):23–7. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Левичева Е.Н., Каменская О.В., Логинова И.Ю. и др. Резервные возможности микроциркуляторного кровотока периферических тканей при циркуляторной гипоксии. Регионарное кровообращение и микроциркуляция 2012;3(11):34–8. [Levicheva E.N., Kamenskaya O.V., Loginova I.Yu. et al. Back microcirculatory blood flow of peripheral tissues in circulatory hypoxia. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya = Regional Hemodynamics and Microcirculation 2012;3(11):34–8. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Левичева Е.Н., Каменская О.В., Логинова И.Ю. и др. Резервные возможности микроциркуляторного кровотока периферических тканей при циркуляторной гипоксии. Регионарное кровообращение и микроциркуляция 2012;3(11):34–8. [Levicheva E.N., Kamenskaya O.V., Loginova I.Yu. et al. Back microcirculatory blood flow of peripheral tissues in circulatory hypoxia. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya = Regional Hemodynamics and Microcirculation 2012;3(11):34–8. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Александрова О.М. Состояние кровотока в сосудах микроциркуляторного русла у больных гипертонической болезнью. Вестник новых медицинских технологий 2008;15(1):147–50. [Aleksandrova O.M. The status of blood flow in the microcirculatory vessels in patients with hypertension. Vestnik novykh meditsinskikh tekhnolologiy = Bulletin of New Medical Technologies 2008;15(1):147–50. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Александрова О.М. Состояние кровотока в сосудах микроциркуляторного русла у больных гипертонической болезнью. Вестник новых медицинских технологий 2008;15(1):147–50. [Aleksandrova O.M. The status of blood flow in the microcirculatory vessels in patients with hypertension. Vestnik novykh meditsinskikh tekhnolologiy = Bulletin of New Medical Technologies 2008;15(1):147–50. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Messner B., Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 2014;34(3):509–15.</mixed-citation><mixed-citation xml:lang="ru">Messner B., Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 2014;34(3):509–15.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Иванов А.Н., Гречихин А.А., Норкин И.А., Пучиньян Д.М. Методы диагностики эндотелиальной дисфункции. Регионарное кровообращение и микроциркуляция 2014;13(4):4–11. [Ivanov A.N., Grechikhin A.A., Norkin I.A., Puchin’yan D.M. Methods of endothelial dysfunction diagnosis. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya = Regional Hemodynamics and Microcirculation 2014;13(4):4–11. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Иванов А.Н., Гречихин А.А., Норкин И.А., Пучиньян Д.М. Методы диагностики эндотелиальной дисфункции. Регионарное кровообращение и микроциркуляция 2014;13(4):4–11. [Ivanov A.N., Grechikhin A.A., Norkin I.A., Puchin’yan D.M. Methods of endothelial dysfunction diagnosis. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya = Regional Hemodynamics and Microcirculation 2014;13(4):4–11. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Maupoint J., Besnier M., Gomez E. et al. Selective vascular endothelial protection reduces cardiac dysfunction in chronic heart failure. Circ Heart Fail 2016;9(4):e002895.</mixed-citation><mixed-citation xml:lang="ru">Maupoint J., Besnier M., Gomez E. et al. Selective vascular endothelial protection reduces cardiac dysfunction in chronic heart failure. Circ Heart Fail 2016;9(4):e002895.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. House S.L., Castro A.M., Lupu T.S. et al. Endothelial fibroblast growth factor receptor signaling is required for vascular remodeling following cardiac ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2016;310(5):H559–71.</mixed-citation><mixed-citation xml:lang="ru">House S.L., Castro A.M., Lupu T.S. et al. Endothelial fibroblast growth factor receptor signaling is required for vascular remodeling following cardiac ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2016;310(5):H559–71.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Fang Y.C., Yeh C.H. Role of microRNAs in vascular remodeling. Curr Mol Med 2015;15(8):684–96.</mixed-citation><mixed-citation xml:lang="ru">Fang Y.C., Yeh C.H. Role of microRNAs in vascular remodeling. Curr Mol Med 2015;15(8):684–96.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Harvey A., Montezano A.C., Touyz R.M. Vascular biology of ageing – implications in hypertension. J Mol Cell Cardiol 2015;83:112–21.</mixed-citation><mixed-citation xml:lang="ru">Harvey A., Montezano A.C., Touyz R.M. Vascular biology of ageing – implications in hypertension. J Mol Cell Cardiol 2015;83:112–21.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Marconi A., Darquenne S., Boulmerka A. et al. Naftidrofuryl-driven regulation of endothelial ICAM-1 involves nitric oxide. Free Radic Biol Med 2003;34(5):616–25.</mixed-citation><mixed-citation xml:lang="ru">Marconi A., Darquenne S., Boulmerka A. et al. Naftidrofuryl-driven regulation of endothelial ICAM-1 involves nitric oxide. Free Radic Biol Med 2003;34(5):616–25.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. Hong H., Mackey W.C. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication. Clin Ther 2014;36(8):1290–301.</mixed-citation><mixed-citation xml:lang="ru">Hong H., Mackey W.C. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication. Clin Ther 2014;36(8):1290–301.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Кузнецов М.Р., Косых И.В., Юмин С.М. и др. Применение нафтидрофурила в ангиологии. Ангиология и сосудистая хирургия 2014;20(4):27–35. [Kuznetsov M.R., Kosykh I.V., Yumin S.M. et al. Use of naftidrofuryl in angiology. Angiologiya i sosudistaya khirurgiya = Angiology and Vascular Surgery 2014;20(4):27–35. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Кузнецов М.Р., Косых И.В., Юмин С.М. и др. Применение нафтидрофурила в ангиологии. Ангиология и сосудистая хирургия 2014;20(4):27–35. [Kuznetsov M.R., Kosykh I.V., Yumin S.M. et al. Use of naftidrofuryl in angiology. Angiologiya i sosudistaya khirurgiya = Angiology and Vascular Surgery 2014;20(4):27–35. (In Russ.)].</mixed-citation></citation-alternatives></ref></ref-list></back></article>
